Our Vision
To transform cancer care by making metastasis preventable, predictable, and precisely treatable.
MetaMol envisions a future where cancer no longer claims lives through silent dissemination and relapse. By targeting the molecular drivers of metastasis at their origin, we aim to redefine therapeutic success — from temporary tumor suppression to durable, systemic protection.
Our Mission
MetaMol Theranostics is pioneering a new frontier in oncology by developing breakthrough diagnostic tools and anti-metastasis therapies rooted in over two decades of research into the cancer-specific molecule Osteopontin-c (hOPNc). Our mission is to empower physicians with precise, individualized insights into cancer risk and to revolutionize treatment for patients with advanced disease.
The Problem
Current chemotherapies primarily suppress tumor growth but fail to eliminate disseminating cancer cells. As a result, relapse frequently occurs in distant organs from cells that survived the initial treatment. Tumor cell dissemination is an early and fundamental event in cancer progression. Therefore, meaningful protection from metastasis and recurrence requires therapies that directly inhibit the molecular mechanisms underlying cancer invasiveness and anchorage-independence – the two essential processes that enable metastasis.
Our Commitment
& Solution
MetaMol’s strategy is grounded in breakthrough research on hOPNc, a tumor-specific variant of Osteopontin. This tumor-derived form plays a distinct and critical role in metastasis. Our research revealed:
hOPNc is present in 75–80% of breast cancers
hOPNc in breast lumps that are not yet cancerous is a predictor of cancer risk
It is completely absent in normal breast tissue
It strongly promotes anchorage-independence, enabling cancer cells to survive in circulation, which is essential for metastasis formation
These discoveries establish hOPNc as:
A highly specific
diagnostic biomarker
for tumor aggressiveness
A functionally critical
therapeutic target
A molecular vulnerability present in the majority of breast (and several other) cancers
MetaMol is actively developing hOPNc inhibitors, with the goal of suppressing metastatic capacity rather than merely shrinking tumors.
By targeting a molecule that drives metastasis in most breast cancers – and is absent in normal tissue – MetaMol aims to deliver transformative treatment options to the majority of patients who currently succumb to metastatic disease.
The Founder
Georg F. Weber attended medical school in Würzburg, Germany. He worked at the Dana-Farber Cancer Institute, Harvard Medical School from 1990 through 1999 and is currently Professor at the University of Cincinnati. Georg F. Weber has published over120 scientific reports, including in upper-tier professional journals, and various monographs, including textbooks on molecular oncology and anti-cancer drugs. He holds several U.S. and international patents, and has placed constructs and antibodies into the public domain. Supporting his mission to combat cancer dissemination, Georg F. Weber is the founder of MetaMol Theranostics, a company specialized in diagnosis and treatment of cancer metastasis.